We found that TalaA blocked the transition from the G1 to S phase of bladder cancer cells and downregulated CCNA2 and CCNB1, which are well-known therapeutic targets for various cancers (11, 12, 13). Here, CCNA2 is linked to urinary bladder carcinoma.